Background: Studies observing the relationship between pulmonary function and the risk of cognitive impairment in middle-aged and older adults was increasing, but the results were inconsistent. To date, evidence from longitudinal data is scarce and further research is urgently needed.Methods: We used data from the China Health and Retirement Longitudinal Study. Participants were enrolled in 2011/2013 and followed up in 2013, 2015 and 2018. Pulmonary function was assessed via peak expiratory flow (PEF). Cognitive function, measured by episodic memory and mental status, was assessed through a face-to-face interview in each survey.Results: A total of 8,274 participants (52.86% males; mean age, 56.44 years) were included. The scores of global cognition (12.46 versus 11.51, P < 0.001) of men were significantly higher than women at baseline, with a total of 5096 participants (61.59%) declining during the follow-up. Higher baseline PEF was associated with lower absolute decline in global cognition (OR per 1-SD difference 0.921; P = 0.031) and mental status (OR per 1-SD difference 0.9889; P = 0.002) during follow-up in men, and significant associations between higher baseline PEF and a lower absolute decline in the episodic memory were both found in men (OR per 1-SD difference 0.907; P = 0.006) and women (OR per 1-SD difference 0.915; P = 0.022). Second analysis showed that the significant associations between positive PEF variation and a lower rate of 4-year decline in global cognition, mental status and episodic memory were all only found in men. In subgroup analyses, higher PEF at baseline was significantly associated with a lower absolute decline of global cognition among male individuals >60 years. Significant associations between higher PEF at baseline and lower absolute decline in global cognition and episodic memory during follow-up were only found in never-smokers, while higher PEF was related to lower absolute decline in mental status among non-smoking and smoking males.Conclusions: Pulmonary function correlates with cognitive functions in middle-aged and older people, especially males. Additional studies characterizing early and long-term PEF changes are needed.
Immune checkpoint therapy has changed cancer treatment, including non-small cell lung cancer (NSCLC). The unresponsiveness of PD-L1 lo/– tumors to anti–PD-1/PD-L1 immunotherapy is attributed to alternative immune evasion mechanisms that remain elusive. We previously reported that farnesoid X receptor (FXR) was increased in PD-L1 lo/– NSCLC. Herein, we found that immune checkpoint HVEM was positively correlated with FXR but inversely correlated with PD-L1 in NSCLC. HVEM was highly expressed in FXR hi PD-L1 lo NSCLC. Consistently, clinically relevant FXR antagonist dose-dependently inhibited HVEM expression in NSCLC. FXR inhibited cytokine production and cytotoxicity of cocultured CD8 + T cells in vitro, and it shaped an immunosuppressive tumor microenvironment (TME) in mouse tumors in vivo through the HVEM/BTLA pathway. Clinical investigations show that the FXR/HVEM axis was associated with immunoevasive TME and inferior survival outcomes in patients with NSCLC. Mechanistically, FXR upregulated HVEM via transcriptional activation, intracellular Akt, Erk1/2 and STAT3 signals, and G1/S cycle progression in NSCLC cells. In vivo treatment experiments demonstrated that anti-BTLA immunotherapy reinvigorated antitumor immunity in TME, resulting in enhanced tumor inhibition and survival improvement in FXR hi PD-L1 lo mouse Lewis lung carcinomas. In summary, our findings establish the FXR/HVEM axis as an immune evasion mechanism in PD-L1 lo/– NSCLC, providing translational implications for future immunotherapy in this subgroup of patients.
Background: Pulmonary fibrosis (PF) is a progressive interstitial lung disease driven in part by epithelial–mesenchymal transition (EMT), but the upstream epithelial regulators remain undefined, and conventional screens rarely separate causal drivers from bystanders. Methods: We integrated interpretable machine learning (SHAP-interpreted LASSO across five transcriptomic cohorts), single-cell virtual gene knockout (VGKO), protein–protein docking with molecular dynamics, co-immunoprecipitation and surface plasmon resonance, a bleomycin mouse model, and loss-/gain-of-function studies in TGF-β1-stimulated BEAS-2B cells, complemented by AI-guided drug screening. Results: SHAP nominated MT2A as a positively weighted predictor broadly expressed across multiple cell subpopulations, and in silico knockout nominated S100A8 as its leading candidate downstream target, yielding a directional MT2A → S100A8 hypothesis. Docking and molecular dynamics predicted a stable MT2A – S100A8 complex, co-immunoprecipitation recovered both proteins from the same complex in cells, and surface plasmon resonance measured direct binding with an apparent dissociation constant of 88 ± 20 nM. MT2A and S100A8 were co-upregulated in fibrotic mouse lung. In epithelial cells, MT2A knockdown reduced S100A8 and reversed the EMT signature, whereas overexpression amplified it. Reciprocal epistasis placed S100A8 downstream of MT2A as its obligate effector: re-expressing S100A8 restored EMT in MT2A -depleted cells, and silencing S100A8 abolished the pro-fibrotic effect of MT2A overexpression. AI screening nominated BRD-K54403101 as a candidate MT2A binder. Conclusion: We identify MT2A as broadly expressed across single-cell clusters and show that in bronchial epithelial cells MT2A sustains S100A8 , which is necessary and sufficient to drive the EMT program. The experimentally defined MT2A-S100A8 axis is a tractable target in pulmonary fibrosis.
22 October 2025 in Applied Biochemistry and Biotechnology